Last reviewed · How we verify

NCT04937712: CovUrinePTD

Analysis of SARS-CoV2 Urine Viral Particles and Association With Proximal Tubular Dysfunction

Status unknown Last updated 30 August 2021
What this trial tests

trial testing RT-PCR SARS-COV2 in urine in SARS-CoV2 Infection in 34 participants. Status unknown.

Timeline
19 August 2021
Primary endpoint
1 July 2022
1 July 2022

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment34
Start date19 August 2021
Primary completion1 July 2022
Estimated completion1 July 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with SARS-CoV2 Infection or Proximal Tubule Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal is to detect Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) urine viral particles in patients in intensive care units, hospitalized for coronavirus Coronavirus Disease-19 (COVID-19) infection, and correlate the presence of the virus in the urine with proximal tubular dysfunction (defined by the association of at least 2 abnormalities: tubular proteinuria, renal phosphate leak, uricosuria, normoglycemic glycosuria, amino aciduria)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing